Zobrazeno 1 - 10
of 56
pro vyhledávání: '"MAFLD, metabolic associated fatty liver disease"'
Autor:
Jinbiao He, Yu Yang, Fan Zhang, Yanjuan Li, Xiaosi Li, Xuemei Pu, Xudong He, Mei Zhang, Xinxing Yang, Qiuman Yu, Yan Qi, Xuefang Li, Jie Yu
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/7747912a4d9e48b48a18cf0d011dfb0f
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
The COVID-19 pandemic is ongoing and places a substantial burden on healthcare systems worldwide. As we further shed light on different disease characteristics, we identify more and more groups of people at higher risk of poor COVID-19 outcomes. Meta
Externí odkaz:
https://doaj.org/article/96136e8f5e7548f687506ef3b9a06d63
Autor:
Chi-Ho Lee, David Tak-Wai Lui, Raymond Hang-Wun Li, Michele Mae-Ann Yuen, Carol Ho-Yi Fong, Ambrose Pak-Wah Leung, Justin Chiu-Man Chu, Loey Lung-Yi Mak, Tai-Hing Lam, Jean Woo, Yu-Cho Woo, Aimin Xu, Hung-Fat Tse, Kathryn Choon-Beng Tan, Bernard Man-Yung Cheung, Man-Fung Yuen, Karen Siu-Ling Lam
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2023)
BackgroundNon-diabetic overweight/obese metabolic dysfunction-associated fatty liver disease (MAFLD) represents the largest subgroup with heterogeneous liver fibrosis risk. Metabolic dysfunction promotes liver fibrosis. Here, we investigated whether
Externí odkaz:
https://doaj.org/article/7939c6218d83411dab2c3d8f16daaec8
Autor:
Camille Pichon, Maxime Nachit, Justine Gillard, Greetje Vande Velde, Nicolas Lanthier, Isabelle A. Leclercq
Publikováno v:
Frontiers in Nutrition, Vol 9 (2022)
BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Progression toward non-alcoholic steatohepatitis (NASH) is associated with alterations of skeletal muscle. One plausible mec
Externí odkaz:
https://doaj.org/article/0e0e13ee4966406880ac31e13720af6d
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/b2a6e280b1cb4f0681a0497d1f066f7e
Autor:
Jinbiao He, Yu Yang, Fan Zhang, Yanjuan Li, Xiaosi Li, Xuemei Pu, Xudong He, Mei Zhang, Xinxing Yang, Qiuman Yu, Yan Qi, Xuefang Li, Jie Yu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Despite the increase in the global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), no approved drug currently exists for the disease. Poria cocos (Schw.) Wolf (P. cocos) is a medicinal mushroom belonging to a family of pol
Externí odkaz:
https://doaj.org/article/1a3be471e10e462b978d1ce7c0e50c85
Autor:
Wen Wen, Hong Li, Chunyi Wang, Chen Chen, Jiake Tang, Mengyun Zhou, Xuwei Hong, Yongran Cheng, Qi Wu, Xingwei Zhang, Zhanhui Feng, Mingwei Wang
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundMetabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the
Externí odkaz:
https://doaj.org/article/aa07a60a82be43549f51f0aab9e67f4c
Autor:
Raphaël Decoin, Laura Butruille, Thomas Defrancq, Jordan Robert, Nicolas Destrait, Augustin Coisne, Samy Aghezzaf, Eloise Woitrain, Zouriatou Gouda, Sofia Schino, Cédric Klein, Patrice Maboudou, François Brigadeau, Didier Klug, Andre Vincentelli, David Dombrowicz, Bart Staels, David Montaigne, Sandro Ninni
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundA number of epidemiological studies have suggested an association between metabolic dysfunction-associated fatty liver disease (MAFLD) and the incidence of atrial fibrillation (AF). However, the pathogenesis leading to AF in the context of
Externí odkaz:
https://doaj.org/article/a64a1b19696149678774d238dc4c9c47
Autor:
Zhang Yong, Huang Zibao, Zhou Zhi, Ma Ning, Wang Ruiqi, Chen Mimi, He Xiaowen, Dong Lin, Xia Zhixuan, Liu Qiang, Lu Weiying, Zhang Xiaopo
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Metabolic-associated fatty liver disease (MAFLD) is becoming more common due to lifestyle changes. A long-term high-fat and high-glucose diet induces glycolipid metabolism disorders in the liver, which results in the development of MAFLD. To date, th
Externí odkaz:
https://doaj.org/article/c66c68bc4a0940eda2ed4a2f3db762b4
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Trimethylamine-N-oxide (TMAO) is a molecular metabolite derived from the gut flora, which has recently emerged as a candidate risk factor for metabolic dysfunction-associated fatty liver disease (MAFLD). TMAO is mainly derived from gut, where the gut
Externí odkaz:
https://doaj.org/article/d6ff85092bf94c008bc87479e82bfb4f